CN101176708A - Carmofur sustained-release implantation agent for curing entity tumour - Google Patents
Carmofur sustained-release implantation agent for curing entity tumour Download PDFInfo
- Publication number
- CN101176708A CN101176708A CNA2007102028868A CN200710202886A CN101176708A CN 101176708 A CN101176708 A CN 101176708A CN A2007102028868 A CNA2007102028868 A CN A2007102028868A CN 200710202886 A CN200710202886 A CN 200710202886A CN 101176708 A CN101176708 A CN 101176708A
- Authority
- CN
- China
- Prior art keywords
- carmofur
- mannitol
- sorbitol
- sustained
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 title claims abstract description 230
- 229960003261 carmofur Drugs 0.000 title claims abstract description 228
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 127
- 238000013268 sustained release Methods 0.000 title claims description 98
- 239000012730 sustained-release form Substances 0.000 title claims description 98
- 238000002513 implantation Methods 0.000 title claims description 48
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 96
- 229930195725 Mannitol Natural products 0.000 claims abstract description 96
- 239000000594 mannitol Substances 0.000 claims abstract description 96
- 235000010355 mannitol Nutrition 0.000 claims abstract description 96
- 239000007943 implant Substances 0.000 claims abstract description 95
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 68
- 239000000600 sorbitol Substances 0.000 claims abstract description 68
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 68
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 57
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 229920002101 Chitin Polymers 0.000 claims abstract description 14
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 3
- 102000009027 Albumins Human genes 0.000 claims abstract description 3
- 108010088751 Albumins Proteins 0.000 claims abstract description 3
- 102000008186 Collagen Human genes 0.000 claims abstract description 3
- 108010035532 Collagen Proteins 0.000 claims abstract description 3
- 108010010803 Gelatin Proteins 0.000 claims abstract description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920000159 gelatin Polymers 0.000 claims abstract description 3
- 239000008273 gelatin Substances 0.000 claims abstract description 3
- 235000019322 gelatine Nutrition 0.000 claims abstract description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 3
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000000811 xylitol Substances 0.000 claims abstract description 3
- 235000010447 xylitol Nutrition 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 3
- 229960002675 xylitol Drugs 0.000 claims abstract description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 106
- 239000004626 polylactic acid Substances 0.000 claims description 59
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 55
- 239000011780 sodium chloride Substances 0.000 claims description 51
- 229920000954 Polyglycolide Polymers 0.000 claims description 42
- 239000004633 polyglycolic acid Substances 0.000 claims description 42
- 230000001093 anti-cancer Effects 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- RTXHNOBSQMHTSB-UHFFFAOYSA-N naphthalen-2-yl 2-hydroxypropanoate Chemical compound C1=CC=CC2=CC(OC(=O)C(O)C)=CC=C21 RTXHNOBSQMHTSB-UHFFFAOYSA-N 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000001514 prostate carcinoma Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 201000010174 renal carcinoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- -1 chrondroitin Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002077 nanosphere Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 32
- 238000000034 method Methods 0.000 abstract description 27
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 238000012148 non-surgical treatment Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 229920002567 Chondroitin Polymers 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 231100000057 systemic toxicity Toxicity 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 23
- 239000003960 organic solvent Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
| Embodiment one | 1 day | 3 days | 5 days | 7 days | 14 days | 21 days | 28 days | 35 days | 42 days | 56 days |
| (A) | 1.2 | 2.2 | 3.4 | 4.6 | 12 | 50 | 70 | 82 | 96 | 100 |
| (a) | 2 | 8 | 14 | 22 | 40 | 50 | 60 | 72 | 84 | 92 |
| (B) | 2 | 4 | 4.6 | 7 | 8 | 48 | 72 | 78 | 86 | 98 |
| (b) | 2.4 | 12 | 18 | 24 | 48 | 54 | 62 | 76 | 88 | 96 |
| (C) | 2.1 | 3.3 | 4.2 | 6 | 10 | 62 | 80 | 88 | 96 | 98 |
| (c) | 2.0 | 7.9 | 16 | 23.6 | 42.8 | 56 | 64 | 78 | 84 | 92 |
| (D) | 1.2 | 3.1 | 5.2 | 6.8 | 10 | 58 | 78 | 89 | 96 | 100 |
| (d) | 3 | 7.2 | 18 | 24 | 41 | 52 | 68 | 80 | 90 | 98 |
| (E) | 1.1 | 3.0 | 5.0 | 7.3 | 8.2 | 58 | 76 | 86 | 94 | 98 |
| (e) | 2.1 | 11 | 18 | 26.0 | 39 | 52 | 68 | 82 | 88 | 94 |
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710202886A CN100586435C (en) | 2007-12-06 | 2007-12-06 | A kind of carmofur sustained-release implant for treating solid tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710202886A CN100586435C (en) | 2007-12-06 | 2007-12-06 | A kind of carmofur sustained-release implant for treating solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101176708A true CN101176708A (en) | 2008-05-14 |
| CN100586435C CN100586435C (en) | 2010-02-03 |
Family
ID=39403229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710202886A Expired - Fee Related CN100586435C (en) | 2007-12-06 | 2007-12-06 | A kind of carmofur sustained-release implant for treating solid tumors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100586435C (en) |
-
2007
- 2007-12-06 CN CN200710202886A patent/CN100586435C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100586435C (en) | 2010-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101185633A (en) | Neratinib sustained-release implant for treating solid tumor | |
| CN101176713B (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
| CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
| CN101185627B (en) | Nilotinib sustained-release implant for treating solid tumor | |
| CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
| CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
| CN101204366A (en) | Melphalan sustained-release implant treating for solid tumor | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN101176710A (en) | Mitoxantrone sustained-release implantation agent for curing entity tumour | |
| CN101176712A (en) | Nimustine sustained-release implantation agent for curing entity tumour | |
| CN101176714A (en) | Meifaron sustained-release implantation agent for curing entity tumour | |
| CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
| CN101181231B (en) | Sustained-release implantation agent of urotrotiken | |
| CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
| CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
| CN101176709A (en) | Beisalutin sustained-release implantation agent for curing entity tumour | |
| CN101229119A (en) | Sustained release ocular implant for treating solid tumors | |
| CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour | |
| CN101185625B (en) | Rubitecan sustained-release implant for treating solid tumor | |
| CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD. Effective date: 20120815 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120815 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100203 Termination date: 20161206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |